CD4 and neoplasm: Alternatively, TCRs cloned from DP CD4+ TILs reactive against patient-matched tumor (neo)antigens could be used to develop TCR-engineered T cells from the patient’s peripheral blood for adoptive transfer as an interventional therapy (16, 17).